An observational study in MRSA Infections, sponsored by CAMC Health System. Completed at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by CAMC Health System · Observational
This study prospectively selects the patients to examine the effectiveness of the investigators' current standard of prophylaxis prior to vascular surgery and to compare the effectiveness of vancomycin and daptomycin plus cefazolin in reducing infections in vascular surgical patients.
According to Medqic.org (site for the Surgical Care Improvement Project) the current recommended drug of choice for prophylaxis prior to vascular surgery is Cefazolin (Ancef). The exception would be to allow the use of Vancomycin as an acceptable antibiotic for patients undergoing cardiac, vascular or orthopedic surgery due to the increasing risk of methicillin-resistantStaphylococcus aureus (MRSA). The significance of the study is to demonstrate that MRSA coverage is needed in vascular surgery with prosthetic graft placement in areas of the body that is at high risk for infection. By decreasing post surgical site and prosthetic infections, we could significantly reduce vascular surgery mortality and morbidity. Cost and amputation rates we feel could also be reduced. patients will be randomized in three groups such as cefazolin,vancomycin and cefazolin, daptomycin and cefazolin and then patients will be monitored per usual post-operative course (30 days and 90 days follow-up) with wound and incision evaluation. Outcome measures include hospital length of stay, the presence of a graft infection, skin infection at incision site, vascular procedure failure secondary to infection, cost, thirty day readmits, amputation, and mortality.
Patients 18 years of age and older undergoing a vascular surgery and or vascular access (vascular fistula or vascular graft) procedure were eligible for enrollment in the study.
Exclusion Criteria:
Overall Number of Participants With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections.
Time frame: 30 days post-operative
Overall Groin Procedures in Patients With and Without Any Infection.
Time frame: 30 days post-operative
recruitment was done during the period August 2007 through June 2009 at vascular center.
| Milestone | Ancef | Daptomycin and Cefazolin | Vancomycin and Cefazolin |
|---|---|---|---|
| Started | 67 | 54 | 60 |
| Completed | 62 | 51 | 56 |
| Not completed | 5 | 3 | 4 |
| participants | Ancef | Daptomycin and Cefazolin | Vancomycin and Cefazolin |
|---|---|---|---|
| Overall Number of Participants With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections. | 2 | 0 | 4 |
| Participants | Total Patients With Infection | Patients Without Infection |
|---|---|---|
| Overall Groin Procedures in Patients With and Without Any Infection. | 14 | 83 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Patients | — | — | — |
| Age, Continuous(years) | Ancef | Daptomycin and Cefazolin | Vancomycin and Cefazolin | Total |
|---|---|---|---|---|
| Mean | 64.37 ± 11.78 | 66.78 ± 11.81 | 64.36 ± 11.12 | 65.17 ± 11.57 |
| Sex: Female, Male(Participants) | Ancef | Daptomycin and Cefazolin | Vancomycin and Cefazolin | Total |
|---|---|---|---|---|
| Female | 26 | 20 | 20 | 66 |
| Male | 41 | 34 | 40 | 115 |
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CAMC Health System